CMS ends Biden-era proposal to expand Medicare coverage of anti-obesity drugs. Seniors continue paying out of pocket for ...

Administration officials reversed a decision made during the Biden presidency that would have given millions of people access ...

The Centers for Medicare and Medicaid Services said it would not cover the medications under Medicare’s Part D coverage.

The Centers for Medicare and Medicaid Services said late Friday that it would not cover medications such as Wegovy that are ...

As semaglutide-based weight loss treatments such as Ozempic and Wegovy become more popular, new side effects are emerging – ...

Novo Holdings, the controlling shareholder of obesity drugmaker Novo Nordisk, nearly doubled annual income and investment ...

The Biden administration proposal would have significantly expanded access to obesity to millions of Americans but would have cost the government billions.

This week has been a brutal reminder of how politics and politicians like to work and be seen. How important it is to be the ...

Novo Holdings, the controlling shareholder of obesity drugmaker Novo Nordisk, nearly doubled annual income and investment ...

Contrave and Wegovy are both weight loss medications. Learn about their effectiveness, side effects, costs, and which ...

Popular medications for obesity and diabetes have been linked to an increased risk of hair loss, particularly for women. Researchers and doctors weigh in.

The Centers for Medicare and Medicaid Services (CMS) announced Friday it will not be finalizing a rule proposed by the Biden ...